4565 Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,440.00 |
52 Week High | JP¥3,175.00 |
52 Week Low | JP¥1,296.00 |
Beta | 0.60 |
1 Month Change | -5.20% |
3 Month Change | -4.95% |
1 Year Change | -52.94% |
3 Year Change | -8.86% |
5 Year Change | -30.97% |
Change since IPO | -29.24% |
Recent News & Updates
Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Mar 08Shareholder Returns
4565 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 0.8% | 1.6% | 1.0% |
1Y | -52.9% | 2.8% | 24.0% |
Return vs Industry: 4565 underperformed the JP Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: 4565 underperformed the JP Market which returned 24% over the past year.
Price Volatility
4565 volatility | |
---|---|
4565 Average Weekly Movement | 6.5% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 4.0% |
10% most volatile stocks in JP Market | 7.7% |
10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4565 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4565's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 350 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
4565 fundamental statistics | |
---|---|
Market cap | JP¥130.54b |
Earnings (TTM) | -JP¥9.07b |
Revenue (TTM) | JP¥16.43b |
7.9x
P/S Ratio-14.3x
P/E RatioIs 4565 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4565 income statement (TTM) | |
---|---|
Revenue | JP¥16.43b |
Cost of Revenue | JP¥4.20b |
Gross Profit | JP¥12.23b |
Other Expenses | JP¥21.31b |
Earnings | -JP¥9.07b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -100.91 |
Gross Margin | 74.44% |
Net Profit Margin | -55.20% |
Debt/Equity Ratio | 102.7% |
How did 4565 perform over the long term?
See historical performance and comparison